ASX:ACR

Acrux (ACR) Stock Price, News & Analysis

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
4,000 shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
11.66%
Price Target
N/A
ACR stock logo

About Acrux Stock (ASX:ACR)

Acrux Limited, together with its subsidiaries, develops and commercializes generic and topical pharmaceuticals in Australia, Europe, the United States, and internationally. The company offers testosterone solutions, such as oral tablets, buccal tablets, subcutaneous pellets, transdermal patches, injections, and topical gels for treatment of males. It also provides estradiol transdermal sprays for women under the Evamist and Lenzetto brand names for the treatment of flushes associated with menopause; and lidocaine and prilocaine cream, a generic version of EMLA cream, which is indicated as a topical anaesthetic for use on normal intact skin for local analgesia, and genital mucous membranes for superficial minor surgery and as a pre-treatment for infiltration anaesthesia. The company was incorporated in 1998 and is based in West Melbourne, Australia.

ACR Stock News Headlines

The Best AI Stock to Own in the World Today is Trading for Just $25
“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.
The Best AI Stock to Own in the World Today is Trading for Just $25
“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.
‘Poker star’s’ luxury yacht sunk by fire
See More Headlines
Receive ACR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acrux and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/21/2019
Today
4/24/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
2,018
Year Founded
N/A

Profitability

Net Income
$-7,660,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$11.42 million
Book Value
A$0.02 per share

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
1.19
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

ACR Stock Analysis - Frequently Asked Questions

How were Acrux's earnings last quarter?

Acrux Limited (ASX:ACR) issued its earnings results on Thursday, February, 21st. The company reported ($0.02) EPS for the quarter. Acrux had a negative trailing twelve-month return on equity of 12.21% and a negative net margin of 6.21%.

Is Acrux a good dividend stock?

Acrux (ASX:ACR) pays an annual dividend of A$0.09 per share and currently has a dividend yield of 11.66%. ACR has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer.

What other stocks do shareholders of Acrux own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Acrux investors own include ANZ Group (ANZ), Lynas Rare Earths (LYC), Altium (ALU), Atlas Iron (AGO), Hugo Boss (BOSS), BHP Group (BHP), Beacon Roofing Supply (BECN), Billabong International (BBG), Abraxas Petroleum (AXAS) and Ausdrill (ASL).

This page (ASX:ACR) was last updated on 4/25/2024 by MarketBeat.com Staff

From Our Partners